Rigel Pharmaceuticals (RIGL) reported a significant financial turnaround in Q2, posting earnings of $59.61 million ($3.28 EPS) compared to a $1.03 million loss (-$0.06 EPS) in the same period last year. This strong performance was fueled by a substantial increase in revenue to $101.68 million, up from $36.84 million year-over-year. The company also provided full-year revenue guidance of $270-$280 million, signaling continued positive momentum.
Rigel Pharmaceuticals (RIGL) demonstrated a significant financial turnaround in its second-quarter results, shifting from a net loss to substantial profitability. The company reported earnings of $59.61 million, or $3.28 per share, a stark reversal from the $1.03 million loss, or -$0.06 per share, recorded in the same period last year. This bottom-line improvement was driven by a powerful surge in revenue, which grew 176% year-over-year to $101.68 million from $36.84 million. While the performance is exceptionally strong, the company's full-year revenue guidance of $270 million to $280 million warrants careful consideration. The Q2 revenue alone accounts for approximately 37% of the midpoint of this annual forecast, implying that the revenue run-rate is expected to moderate in the second half of the year and that the Q2 figure may have included non-recurring items.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.85
Ticker Sentiment
